Apellis Pharmaceuticals 관리

관리 기준 확인 2/4

Apellis Pharmaceuticals CEO는 Cedric Francois, Sep2009 에 임명되었습니다 의 임기는 15.67 년입니다. 총 연간 보상은 $ 10.96M, 7.2% 로 구성됩니다. 7.2% 급여 및 92.8% 보너스(회사 주식 및 옵션 포함). 는 € 26.08M 가치에 해당하는 회사 주식의 1.35% 직접 소유합니다. 26.08M. 경영진과 이사회의 평균 재임 기간은 각각 7.6 년과 9.8 년입니다.

주요 정보

Cedric Francois

최고 경영자

US$11.0m

총 보상

CEO 급여 비율	7.24%
CEO 임기	15.7yrs
CEO 소유권	1.4%
경영진 평균 재임 기간	7.6yrs
이사회 평균 재임 기간	9.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Cedric Francois 의 보수는 Apellis Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2025	n/a	n/a	-US$224m
Dec 31 2024	US$11m	US$793k	-US$198m
Sep 30 2024	n/a	n/a	-US$250m
Jun 30 2024	n/a	n/a	-US$333m
Mar 31 2024	n/a	n/a	-US$417m
Dec 31 2023	US$10m	US$735k	-US$529m
Sep 30 2023	n/a	n/a	-US$606m
Jun 30 2023	n/a	n/a	-US$657m
Mar 31 2023	n/a	n/a	-US$691m
Dec 31 2022	US$9m	US$681k	-US$652m
Sep 30 2022	n/a	n/a	-US$634m
Jun 30 2022	n/a	n/a	-US$638m
Mar 31 2022	n/a	n/a	-US$702m
Dec 31 2021	US$9m	US$647k	-US$746m
Sep 30 2021	n/a	n/a	-US$520m
Jun 30 2021	n/a	n/a	-US$460m
Mar 31 2021	n/a	n/a	-US$360m
Dec 31 2020	US$9m	US$619k	-US$345m
Sep 30 2020	n/a	n/a	-US$536m
Jun 30 2020	n/a	n/a	-US$470m
Mar 31 2020	n/a	n/a	-US$423m
Dec 31 2019	US$4m	US$560k	-US$305m
Sep 30 2019	n/a	n/a	-US$228m
Jun 30 2019	n/a	n/a	-US$194m
Mar 31 2019	n/a	n/a	-US$156m
Dec 31 2018	US$4m	US$550k	-US$128m

보상 대 시장: Cedric 의 총 보상 ($USD 10.96M )은 German 시장( $USD 1.71M ).

보상과 수익: 회사가 수익성이 없는 동안 Cedric 의 보상이 증가했습니다.

CEO

Cedric Francois (52 yo)

15.7yrs

테뉴어

US$10,957,451

보상

Dr. Cedric Francois, M.D., Ph.D. serves as Principal of Vista Therapeutics, Inc. Dr. Francois co-founded Apellis Pharmaceuticals, Inc. in 2009 and has been its Chief Executive Officer, President and Direct...

리더십 팀

이름	위치	테뉴어	보상	소유권
Cedric Francois	Co-Founder	15.7yrs	US$10.96m	1.35% € 26.1m
Alec Machiels	Co-Founder & Director	16.3yrs	US$492.47k	0.62% € 11.9m
Timothy Sullivan	CFO & Treasurer	7.6yrs	US$3.95m	0.088% € 1.7m
David Watson	General Counsel & Secretary	11.3yrs	US$3.89m	0.098% € 1.9m
Caroline Baumal	Chief Medical Officer	2.3yrs	US$4.41m	0.013% € 258.7k
Pascal Deschatelets	Co-Founder & Chief Scientific Officer	15.7yrs	US$3.08m	0.89% € 17.2m
James Chopas	VP, Corporate Controller & Chief Accounting Officer	3.8yrs	데이터 없음	0.014% € 278.2k
Meredith Kaya	Senior Vice President	no data	데이터 없음	데이터 없음
Peter Hillmen	Head of Hematology Engagement & Member of PNH Scientific Advisory Board	3yrs	데이터 없음	데이터 없음
Victoria Brown	Senior Vice President	6.3yrs	데이터 없음	데이터 없음
Nur Nicholson	Chief Technical Operations Officer	no data	US$3.02m	0.017% € 324.7k
David Acheson	Executive Vice President of Commercial	no data	데이터 없음	데이터 없음

7.6yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: 1JK 의 관리팀은 노련하고 경험 (평균 재직 기간 7.6 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Cedric Francois	Co-Founder	15.7yrs	US$10.96m	1.35% € 26.1m
Alec Machiels	Co-Founder & Director	15.7yrs	US$492.47k	0.62% € 11.9m
Peter Hillmen	Head of Hematology Engagement & Member of PNH Scientific Advisory Board	9.8yrs	데이터 없음	데이터 없음
Lokchung L. Chan	Independent Chairman of the Board	11.8yrs	US$498.72k	0.00076% € 14.7k
Stephanie O'Brien	Independent Director	11.8yrs	US$484.97k	0.00076% € 14.7k
Gabriel Coscas	Member of AMD Scientific Advisory Board	9.8yrs	데이터 없음	데이터 없음
Robert Brodsky	Member of PNH Scientific Advisory Board	9.8yrs	데이터 없음	데이터 없음
Michael Yeadon	Member of Pulmonology Scientific Advisory Board	9.8yrs	데이터 없음	데이터 없음
Paul Fonteyne	Independent Director	5.1yrs	US$487.47k	0.0047% € 91.5k
A. Dunlop	Independent Director	15.2yrs	US$477.47k	0.12% € 2.2m
Marsha Wills-Karp	Member of Pulmonology Scientific Advisory Board	no data	데이터 없음	데이터 없음
Carl Atkinson	Member of Pulmonology Scientific Advisory Board	9.8yrs	데이터 없음	데이터 없음

9.8yrs

평균 재임 기간

57.5yo

평균 연령

경험이 풍부한 이사회: 1JK 의 이사회는 경험(평균 재직 기간 9.8 년)으로 간주됩니다.

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/05/25 05:57
장 마감 주가	2025/05/23 00:00
수익	2025/03/31
연간 수익	2024/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Apellis Pharmaceuticals, Inc. 35 애널리스트 중 21 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Colleen Kusy	Baird
Michael Ulz	Baird
Ishan Majumdar	Baptista Research

Apellis Pharmaceuticals 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 03, 2025

Apellis Pharmaceuticals, Inc Announces Craig Wheeler to Join the Board of Directors, Effective April 21, 2025

Apellis Pharmaceuticals, Inc. Announces Executive Changes

Apellis Pharmaceuticals Appoints Keli Walbert to the Board of Directors

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Chief Technical Operations Officer recently sold €590k worth of stock

Recent updates

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 03, 2025

Apellis Pharmaceuticals, Inc Announces Craig Wheeler to Join the Board of Directors, Effective April 21, 2025

Apellis Pharmaceuticals, Inc. Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for Empaveli (pegcetacoplan) for C3G and Primary IC-MPGN

Apellis Pharmaceuticals, Inc. and Sobi Announces EMA Validation of Indication Extension Application for Aspaveli®? (Pegcetacoplan) for C3g and Primary Ic-Mpgn

Apellis Receives Approval of SYFOVRE (pegcetacoplan) in Australia for Geographic Atrophy (GA)

Apellis Pharmaceuticals, Inc. Announces Executive Changes

Apellis Pharmaceuticals Appoints Keli Walbert to the Board of Directors

Third quarter 2024 earnings released: US$0.46 loss per share (vs US$1.17 loss in 3Q 2023)

Sobi and Apellis Pharmaceuticals, Inc. Announces Detailed Data from the Phase 3 Valiant Study

Apellis Pharmaceuticals, Inc. Presents Positive Results from the Phase 3 VALIANT Study at Kidney Week

Forecast breakeven date pushed back to 2026

Sobi and Apellis Announce Positive Topline Results from Phase 3 Valiant Study of Pegcetacoplan in C3G and Primary IC-MPGN

Forecast to breakeven in 2025

Second quarter 2024 earnings released: US$0.30 loss per share (vs US$1.02 loss in 2Q 2023)

Apellis Pharmaceuticals, Inc. Announces Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress

First quarter 2024 earnings released: US$0.54 loss per share (vs US$1.56 loss in 1Q 2023)

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency

Chief Technical Operations Officer recently sold €590k worth of stock

Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024

Full year 2023 earnings released: US$4.45 loss per share (vs US$6.15 loss in FY 2022)

Apellis Pharmaceuticals, Inc. Announces Negative CHMP Opinion for Pegcetacoplan for Ga in the European Union and Plans to Seek Re-Examination of Application

Apellis Pharmaceuticals, Inc. Appoints Adam Townsend as Chief Operating Officer

Co-Founder recently sold €482k worth of stock

Apellis Pharmaceuticals, Inc. Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union

Apellis Pharmaceuticals, Inc. and Sobi Presents Post Hoc Data that Reinforce the Long-Term Efficacy and Safety of EMPAVELI

Insufficient new directors

Apellis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G

Apellis Pharmaceuticals, Inc. Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration

Apellis Pharmaceuticals, Inc. Receives Permanent J-Code (J2781) for SYFOVRE® (Pegcetacoplan Injection), Effective October 1, 2023

Levi & Korsinsky, LLP Notifies Investors in Apellis Pharmaceuticals, Inc. of Class Action Securities Lawsuit

Apellis Pharmaceuticals, Inc. Announces Corporate Restructuring to Drive Growth of SYFOVRE and EMPAVELI

Apellis Pharmaceuticals, Inc. Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE (Pegcetacoplan Injection)

Kessler Topaz Meltzer & Check, LLP and Bernstein Litowitz Berger & Grossmann LLP Files Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc

No longer forecast to breakeven

Second quarter 2023 earnings released: US$1.02 loss per share (vs US$1.46 loss in 2Q 2022)

Apellis Pharmaceuticals, Inc. Provides Update on Review of Rare Safety Events with SYFOVRE® for Geographic Atrophy

Insufficient new directors

FDA Approves Syfovre (Pegcetacoplan Injection) as the First and Only Treatment for Geographic Atrophy (GA)

Apellis Appoints Retina Specialist Dr. Caroline Baumal as Chief Medical Officer

Forecast to breakeven in 2025

Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)

Insufficient new directors

Apellis Pharmaceuticals, Inc. Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan NDA for Geographic Atrophy

Apellis Pharmaceuticals, Inc. Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting

Apellis Pharmaceuticals, Inc. Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies in Geographic Atrophy

Apellis Pharmaceuticals, Inc. Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of Geographic Atrophy

Apellis Pharmaceuticals, Inc. Announces Five Oral Presentations in Geographic Atrophy Highlighted at the ASRS Annual Scientific Meeting

Insider recently sold €116k worth of stock

Apellis Pharmaceuticals, Inc and Sobi Report sNew Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) for PNH at EHA 2022 Congress

Apellis Announces Submission of New Drug Application to the FDA for Pegcetacoplan for Geographic Atrophy

No longer forecast to breakeven

Apellis Pharmaceuticals, Inc. Announces Appointment of Peter Hillmen as Head of Hematology Engagement, Effective May 23, 2022

Apellis Pharmaceuticals, Inc. Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy at ARVO Annual Meeting

Insufficient new directors

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2022

No longer forecast to breakeven

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

General Counsel recently sold €51k worth of stock

Forecast to breakeven in 2024

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Announce EU Approval of Aspaveli® (Pegcetacoplan) for Treatment of PNH

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (publ) Report Empaveli™ Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population

Apellis Announces Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Report Positive Top-Line Results from the Phase 3 Prince Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH

Apellis Announces U.S. Food and Drug Administration (Fda) Approval of Empaveli™ (Pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

ApApellis Pharmaceuticals, Inc. to Present Long-Term Pegcetacoplan Data in PNH at the European Hematology Association Virtual Congress

The NEJM Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH

Apellis Pharmaceuticals, Inc. Provides Update on APL-9 for Severe COVID-19